SGO Annual Meeting

Toon Van Gorp, MD, PhD, discussed findings from the MIRASOL trial and the potential of mirvetuximab to redefine treatment paradigms in ovarian cancer.

Sarah Lee, MD, MBA, discussed a study to better disaggregate the subgroup of Asian American patients with ovarian cancer.

ChatGPT was able to answer general questions about genetic counseling for gynecologic cancers, but some obstacles still remain.

A quality initiative study investigated whether offering human papillomavirus vaccines at the time of abortion care could increase vaccination rates.

In heavily pretreated patients with recurrent low-grade serous ovarian cancer, the combination of avutometinib plus defactinib showing promising results within the phase 2 ENGOT-ov60/GOG-3052/RAMP 201 trial.

Ramez N. Eskander, MD, discusses additional targetable biomarkers that could be addressed in a similar combination as what was seen in the phase 3 NRG-GY018/KEYNOTE-868 trial with standard of care chemotherapy.

Thomas J. Herzog, MD, discusses the efficacy data seen in a subgroup analysis of the phase 2 AMPECT study evaluating nab-Sirolimus for patients with perivascular epithelioid sarcoma.

ctDNA offers clinicians the potential to determine whether to proceed with or discontinue PARP inhibitor maintenance therapy in patients with recurrent epithelial ovarian cancer.

Thomas J. Herzog, MD, discusses the safety findings of nab-Sirolimus in a subgroup analysis of the phase 2 AMPECT study looking at patients with perivascular epithelioid sarcoma.

Thomas J. Herzog, MD, discusses the importance of patients seeing a gynecologist oncologist or a sarcoma doctor for gynecologic perivascular epithelioid sarcomas.

Combining ixabepilone with bevacizumab generated improved survival rates and high response rates compared with ixabepilone monotherapy in platinum-resistant or platinum-refractory ovarian cancer.

Ex vivo generation of CD3-positive, CD56-positive Natural Killer-Like (NKT) with CRX100 was successful in all 7 patients with ovarian cancer in a phase 1 trial.

The latest developments across the field of gynecologic oncology were presented at the 2024 Society for Gynecologic Oncology Annual Meeting on Women’s Cancer in San Diego, California, from March 16-18, 2024.

Rezatapopt treatment delivered responses with acceptable toxicity in heavily pretreated patients with advanced ovarian cancer harboring TP53 Y220C mutations.

Findings from the DUO-E study support potential new durvalumab-based treatment options for patients with advanced or recurrent endometrial cancer.

In the phase 3 LEAP-001, the combination of lenvatinib plus pembrolizumab improved progression-free survival and overall survival among patients with endometrial cancer.

The use of ChatGPT may help to improve genetic counseling for patients with gynecologic cancer.

An increased risk of death and lower enrollment in clinical trials have been observed between Black and White patients with endometrial cancer.

Brian Slomovitz, MD, MS, FACOG, discusses the potential use of tisotumab vedotin-tftv in combinations for the treatment of patients with second- or third-line recurrent or metastatic cervical cancer.

Treatment with nab-Sirolimus demonstrated promising response rates in patients with gynecologic PEComa, according to a subgroup analysis of the phase 2 AMPECT study.

A phase 2 study has begun enrolling patients with 0 to 1 prior lines of therapy to receive the mTOR inhibitor nab-Sirolimus plus letrozole for advanced or recurrent endometrioid carcinoma.

In locally advanced cervical cancer, the combination of neoadjuvant tislelizumab plus chemotherapy was demonstrated to be safe with encouraging antitumor activity.

Patient reported health-related quality of life outcomes from the phase 3 MIRASOL trial strengthen the case for mirvetuximab soravtansine as a new standard of care for patients with folate receptor-alpha positive ovarian cancer resistant to platinum chemotherapy.

Olaparib plus cediranib did not improve survival compared with chemotherapy in patients with platinum-resistant or -refractory epithelial ovarian cancer.

An unprecendented survival benefit was demonstrated with dostarlimab plus in patients with microsatellite instability-high primary advanced or recurrent endometrial cancer.

Findings from the KEYNOTE-868 trial demonstrated a positive survival outcome with pembrolizumab plus chemotherapy across endometrial cancer subgroups.

Rates of cervical cancer across the United States vary due to social determinants of health.

New results from the phase 3 RUBY trial make the case for the use of dostarlimab in addition to chemotherapy as a standard of care for patients with recurrent endometrial cancer.

Phase 1 data signals promise for botensilimab plus bastilimab for advanced ovarian cancer.

Toripalimab with bevacizumab and platinum-based chemotherapy showed promising response and disease control rates in patients with refractory, recurrent and metastatic cervical cancer.